| |||||||||

Revenue by Geography (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Revenue - International | 9.50B | 9.25B | 8.86B | 9.51B | 10.5B | |||
| Revenue - US | 13.5B | 12.8B | 13.8B | 14.7B | 13.4B | |||
| Total Revenue | 22.9B | 22.0B | 22.6B | 24.2B | 23.9B | |||
Revenue by Segment (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Revenue - Singulair | 0 | 0 | 0 | 4.27B | 4.34B | |||
| Revenue - Cozaar/Hyzaar | 0 | 0 | 0 | 3.35B | 3.56B | |||
| Revenue - Fosamax | 0 | 0 | 0 | 3.05B | 1.55B | |||
| Revenue - Januvia | 0 | 0 | 0 | 668M | 1.40B | |||
| Revenue - Cosopt/Trusopt | 0 | 0 | 0 | 787M | 781M | |||
| Revenue - Zocor | 0 | 0 | 0 | 876M | 660M | |||
| Revenue - Maxalt | 0 | 0 | 0 | 467M | 529M | |||
| Revenue - Propecia | 0 | 0 | 0 | 405M | 429M | |||
| Revenue - Arcoxia | 0 | 0 | 0 | 329M | 377M | |||
| Revenue - Vasotec/Vaseretic | 0 | 0 | 0 | 495M | 357M | |||
| Revenue - Janumet | 0 | 0 | 0 | 86.4M | 351M | |||
| Revenue - Proscar | 0 | 0 | 0 | 411M | 324M | |||
| Revenue - Emend | 0 | 0 | 0 | 204M | 264M | |||
| Revenue - Other Pharmaceutical | 0 | 0 | 0 | 2.42B | 2.28B | |||
| Revenue - Gardasil | 0 | 0 | 0 | 1.48B | 1.40B | |||
| Revenue - ProQuad/M-M-R II/Varivax | 0 | 0 | 0 | 1.35B | 1.27B | |||
| Revenue - RotaTeq | 0 | 0 | 0 | 525M | 664M | |||
| Revenue - Zostavax | 0 | 0 | 0 | 236M | 312M | |||
| Revenue - Hepatitis vaccines | 0 | 0 | 0 | 280M | 148M | |||
| Revenue - Other vaccines | 0 | 0 | 0 | 410M | 355M | |||
| Revenue - Primaxin | 0 | 0 | 0 | 764M | 760M | |||
| Revenue - Cancidas | 0 | 0 | 0 | 537M | 596M | |||
| Revenue - Isentress | 0 | 0 | 0 | 41.3M | 361M | |||
| Revenue - Invanz | 0 | 0 | 0 | 190M | 265M | |||
| Revenue - Other infectious disease | 0 | 0 | 0 | 1.70M | 15.5M | |||
| Revenue - Crixivan/Stocrin | 0 | 0 | 0 | 310M | 275M | |||
| Total Revenue | 22.9B | 22.0B | 22.6B | 24.2B | 23.9B | |||
| ||||||